High concentration ganciclovir eye drops for treating cytomegalovirus retinitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the effectiveness of 2% ganciclovir eye drops in treating cytomegalovirus retinitis. It is a monocentric, single-arm, prospective study where patients will receive the eye drops at varying frequencies over a period of six weeks. The study aims to assess the treatment's impact on visual acuity, intraocular pressure, and other ocular health indicators. All participants will provide informed consent and undergo thorough evaluations throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients voluntarily participate in studies and sign informed consent forms
2. Ages 2-80 years (with cut-off values) male and female
3. One of the following is true （1）In patients with cytomegalovirus retinitis after hematopoietic stem cell transplantation/cord blood transplantation, the white blood cell count is less than 4× 10\^9/L, and the platelet count ranges are 25× 10\^9/L≤ PLT\<100×10\^9/L，Intravitreal injection carries a greater risk of infection and bleeding, and is unable to administer systemic medication due to the bone marrow suppression of antiviral drugs, or systemic medication for severe CMV retinitis cannot be well controlled; （2）In patients with CMVR with AIDS, the CD4+ T cell count is less than 100/μl, there is a great risk of infection with intravitreal injection, and the systemic medication of severe CMV retinitis cannot be well controlled.

Exclusion Criteria:

* Eye condition

  1. The presence of refractive interstitial opacification affects fundus observation;
  2. Intravitreal ganciclovir or sodium phosformate injections were performed within 1 week prior to baseline;
  3. Other diseases that can affect visual function such as syphilis-related eye diseases, acute retinal necrosis, congenital glaucoma, congenital corneal lesions, congenital macular degeneration, etc.
* General condition

  1. Severe neutropenia (\<0.5×10\^9) or severe thrombocytopenia (\< 25× 10\^9/L);
  2. Other investigators judged patients who were not suitable for enrollment;

Where it's running

• Tianjin Medical University Eye Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: xiaomin Zhang
• Email: xiaomzh@126.com
• Phone: +8613920023990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Eye drops made from a child's own blood serum for dry eyes

  This will try eye drops made from each child's own blood serum to see if they help children under 18 with moderate-to-severe dry eye that hasn't improved with artificial tears.

  Recruiting The General Authority for Teaching Hospitals and Institutes · Cairo · NCT07295691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.